Market accessCompany release

Citius Oncology reports LYMPHIR wholesaler purchases up 120% as institutional orders reach 54

🇺🇸 Citius Pharmaceuticals, Inc. (CTXR) · Mon 26 Oct 2026

Preliminary, unaudited figures show wholesalers bought 792 units of the cutaneous T-cell lymphoma therapy in the September quarter, against 360 in the previous quarter.

Citius Oncology has released preliminary, unaudited figures showing a sharp rise in wholesaler purchases of LYMPHIR (denileukin diftitox-cxdl). Wholesalers bought 792 units in the quarter ended 30 September 2026, up from 360 units in the preceding quarter, an increase of 120%.

LYMPHIR is indicated for relapsed or refractory Stage I–III cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy. The company said 54 institutions have now ordered the product, compared with 44 in mid-August.

Citius Oncology has set a goal of securing formulary placement at 100 priority institutions by the end of the calendar year. It plans to report full results in December 2026. Because the current numbers are preliminary and unaudited, they may change when the full results are published.

The figures measure wholesaler purchases rather than patient use, and the company's summary does not provide revenue or prescription data.

What it means for your team

  • Market-access teams should note that the company is targeting formulary placement at 100 priority institutions by year-end, up from 54 institutions that have ordered the product.
  • Wholesaler unit purchases are an early uptake indicator only; they do not show how many patients have been treated.
  • The preliminary, unaudited numbers should be checked against the full results due in December 2026.

Company's press release (SEC filing): Citius Pharmaceuticals, Inc. ↗

Article written by VigiEye from the official source (Citius Pharmaceuticals, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →